000144810 001__ 144810 000144810 005__ 20240912134240.0 000144810 0247_ $$2doi$$a10.1111/cns.12314 000144810 0248_ $$2sideral$$a95854 000144810 037__ $$aART-2014-95854 000144810 041__ $$aeng 000144810 100__ $$aFayed, N 000144810 245__ $$aChanges in metabolites after treatment with memantine in fibromyalgia. A double-blind randomized controlled trial with magnetic resonance spectroscopy with a 6-month follow-up. 000144810 260__ $$c2014 000144810 5203_ $$aAim: To evaluate the efficacy of memantine on metabolite levels in different areas of the brain and to determine whether changes in metabolite levels correlate with clinical variables in Fibromyalgia (FM) patients. Methods: Doubled-blind parallel randomized controlled trial. Twenty-five patients diagnosed with FM were enrolled in the study. Patients were administered questionnaires on pain, anxiety, depression, quality of life, and cognitive impairment, and single-voxel MRS of the brain was performed. All assessments were performed at baseline and after 6 months of treatment with memantine or placebo. Results: Patients treated with memantine exhibited a significant increase in the glutamate (P = 0.010), glutamate/creatine ratio (P = 0.013), combined glutamate + glutamine (P = 0.016) and total N-acetyl-aspartate (NAA+NAAG) (P = 0.034) in the posterior cingulate cortex compared with those on placebo. Furthermore, the memantine group exhibited increases in creatine (P = 0.013) and choline (Cho) (P = 0.025) in the right posterior insula and also a correlation between choline and the Fibromyalgia Impact Questionnaire (FIQ) in the posterior insula (P = 0.050) was observed. Conclusion: Memantine treatment resulted in an increase in cerebral metabolism in FM patients, suggesting its utility for the treatment of the illness. 000144810 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000144810 590__ $$a3.931$$b2014 000144810 591__ $$aPHARMACOLOGY & PHARMACY$$b43 / 255 = 0.169$$c2014$$dQ1$$eT1 000144810 591__ $$aNEUROSCIENCES$$b67 / 251 = 0.267$$c2014$$dQ2$$eT1 000144810 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000144810 700__ $$0(orcid)0000-0001-6565-9699$$aOliván-Blázquez, B$$uUniversidad de Zaragoza 000144810 700__ $$0(orcid)0000-0003-2088-4272$$aHerrera-Mercadal, P$$uUniversidad de Zaragoza 000144810 700__ $$0(orcid)0000-0002-8862-7240$$aPuebla-Guedea, M 000144810 700__ $$0(orcid)0000-0001-5566-9746$$aPérez-Yus, MC$$uUniversidad de Zaragoza 000144810 700__ $$aAndrés, E 000144810 700__ $$0(orcid)0000-0002-1690-4130$$aLópez del Hoyo, Y$$uUniversidad de Zaragoza 000144810 700__ $$0(orcid)0000-0002-5494-6550$$aMagallon, R$$uUniversidad de Zaragoza 000144810 700__ $$aViguera, L 000144810 700__ $$0(orcid)0000-0002-3797-4218$$aGarcia-Campayo, J.$$uUniversidad de Zaragoza 000144810 7102_ $$14009$$2740$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicología Social 000144810 7102_ $$14009$$2730$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicología Básica 000144810 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000144810 7102_ $$10$$2X$$aUniversidad de Zaragoza$$bEstudios propios$$cEstudios Propios Dpto.M.Ps.y D 000144810 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría 000144810 7102_ $$14009$$2680$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Person.Eval.Trat.Psicoló. 000144810 773__ $$g20, 11 (2014), 999-1007$$pCNS Neuroscience & Therapeutics$$tCNS Neuroscience & Therapeutics$$x1755-5930 000144810 8564_ $$s870028$$uhttps://zaguan.unizar.es/record/144810/files/texto_completo.pdf$$yPostprint 000144810 8564_ $$s1287775$$uhttps://zaguan.unizar.es/record/144810/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000144810 909CO $$ooai:zaguan.unizar.es:144810$$particulos$$pdriver 000144810 951__ $$a2024-09-12-13:05:00 000144810 980__ $$aARTICLE